cSCC remains a disease with a significant need for more effective and tolerable treatment options, particularly for patients with concomitant hematological malignancies, solid organ transplant ...

USA: Findings from the PINES trial suggest that eltrombopag (Promacta) may offer improved outcomes for children with newly ...

The US Food and Drug Administration (FDA) has accepted Sobi North America’s avatrombopag (DOPTELET) supplemental new drug ...

The FDA also accepted Sobi’s New Drug Application (NDA) for avatrombopag for oral suspension. Avatrombopag for oral suspension is a capsule where its granules are sprinkled onto a soft food or liquid ...

The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for avatrombopag for the treatment of thrombocytopenia in pediatric patients aged 1 year and older with ...

Cyrus Biotechnology announces potent in vivo redosability of an engineered IdeS protease for IgG-driven autoimmune disease.

Blood disorders are a group of conditions that affect the production, function, or structure of blood cells, leading to ...

Sanofi has presented promising results from a phase 3 study of its investigational oral Bruton’s tyrosine kinase (BTK) ...

Positive results from the pivotal LUNA 3 phase 3 study of rilzabrutinib in adults with persistent or chronic immune thrombocytopenia (ITP), a rare immune-mediated disease, reinforce the efficacy and ...

SAN DIEGO -- Treatment with an investigational oral inhibitor of Bruton's tyrosine kinase (BTK) was safe and boosted platelet ...

The oral BTK inhibitor rilzabrutinib led to rapid and durable platelet responses, reduced bleeding, and improved fatigue in ...

A drug developed by Sanofi raised platelet counts and reduced bleeding episodes in patients with a rare autoimmune disorder ...